(32) demonstrated that the serum concentration of Galectin-3 was significantly elevated in patients with DM combined with reduced LVEF, suggesting that it may be a potential biomarker for identifying the early stages of LVDD in DM patients. This evidence concerns the gene LGALS3 and diabetes mellitus.